2021

1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

   Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255